The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) is a huge mover today! The stock decreased 3.36% or $0.28 during the last trading session, hitting $8.05. About 1.02M shares traded hands. Inovio Pharmaceuticals Inc (NASDAQ:INO) has declined 10.24% since April 13, 2016 and is downtrending. It has underperformed by 14.16% the S&P500.
The move comes after 5 months negative chart setup for the $635.07 million company. It was reported on Nov, 15 by Barchart.com. We have $7.41 PT which if reached, will make NASDAQ:INO worth $50.81M less.
Inovio Pharmaceuticals Inc (NASDAQ:INO) Ratings Coverage
Out of 3 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 2 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 67% are positive. Inovio Pharmaceuticals has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. Brean Capital maintained Inovio Pharmaceuticals Inc (NASDAQ:INO) on Monday, March 14 with “Buy” rating. The firm earned “Hold” rating on Wednesday, August 12 by Zacks. The firm has “Buy” rating given on Tuesday, January 5 by Maxim Group. Maxim Group maintained it with “Buy” rating and $23 target price in Wednesday, September 9 report. The company was maintained on Monday, August 10 by Piper Jaffray. The rating was downgraded by Zacks on Friday, August 14 to “Hold”. The rating was downgraded by Maxim Group on Tuesday, August 9 to “Hold”.
According to Zacks Investment Research, “Inovio Pharmaceuticals, Inc., formerly known as Inovio Biomedical Corporation, is engaged in the discovery, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The Company’s electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. Inovio’s clinical programs include human papillomavirus (HPV)/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) vaccines. It is advancing preclinical research for a universal seasonal/pandemic influenza vaccine. The Company’s partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. Inovio Pharmaceuticals, Inc. is headquartered in Blue Bell, Pennsylvania.”
More notable recent Inovio Pharmaceuticals Inc (NASDAQ:INO) news were published by: Fool.com which released: “The Potential and Peril with Inovio Pharmaceuticals, Inc.” on November 12, 2016, also Fool.com with their article: “Here’s Why Inovio Pharmaceuticals, Inc. Shares Tanked 30.6% in October” published on November 08, 2016, Fool.com published: “Better Buy: Inovio Pharmaceuticals, Inc. vs. Novavax” on October 25, 2016. More interesting news about Inovio Pharmaceuticals Inc (NASDAQ:INO) were released by: Nasdaq.com and their article: “Earnings Reaction History: Inovio Pharmaceuticals, Inc, 54.5% Follow-Through …” published on November 09, 2016 as well as Medgadget.com‘s news article titled: “Inovio Pharmaceuticals, Inc. – Product Pipeline Review – 2016” with publication date: November 12, 2016.
INO Company Profile
Inovio Pharmaceuticals, Inc. (Inovio), incorporated on June 15, 2001, is a bio-pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. The Firm has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers (cervical, head and neck, and anal), prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), influenza, Ebola, Middle East respiratory syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, the Company has a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovio’s immunotherapies consist of one or more DNA plasmids encoding one or more selected antigen that are introduced into cells of humans or animals. Inovio’s immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.